about
Risperidone (depot) for schizophreniaSupportive therapy for schizophreniaHaloperidol versus placebo for schizophreniaRisperidone versus other atypical antipsychotics for schizophreniaAntipsychotic medication for early episode schizophreniaRisperidone dose for schizophreniaRisperidone versus placebo for schizophreniaSupportive therapy for schizophreniaHaloperidol versus placebo for schizophreniaSupportive therapy for schizophreniaDepot risperidone for schizophreniaRisperidone versus typical antipsychotic medication for schizophreniaOff-label indications for atypical antipsychotics: A systematic reviewCatatonia under medication with risperidone in a 61-year-old patientPublication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseAntipsychotic drugs on maternal behavior in rats.Extrapyramidal side-effects of antipsychotics in a randomised trial.Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.The impact of missing data on the results of a schizophrenia study.Quetiapine for schizophrenia.Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.Applying concepts of generalizability theory on clinical trial data to investigate sources of variation and their impact on reliability.Haloperidol versus placebo for schizophrenia.Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysisEstimating reliability and generalizability from hierarchical biomedical data.The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data.Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literaturePharmacological management of aggression and violence.Imputation methods for missing outcome data in meta-analysis of clinical trialsGeneralizability in nongaussian longitudinal clinical trial data based on generalized linear mixed models.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes.Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacologyImproving outcome in schizophrenia: the case for early interventionA comparative review of new antipsychotics.Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia.What proportion of primary psychiatric interventions are based on evidence from randomised controlled trials?Atypical antipsychotics in older adults.New Modified UPLC/Tandem Mass Spectrometry Method for Determination of Risperidone and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Dose-Dependent Pharmacokinetic Study in Sprague-Dawley Rats
P2860
Q24185901-AA6DD68E-F673-4284-8AC3-CDED5C3EFD05Q24186517-40FE56B8-1BD5-4C2E-A91E-6746694C78D0Q24202457-45F14E8D-C26E-4365-B0C8-300B0C39C302Q24234950-370807AB-1608-4D0A-B826-539D1ED874B9Q24236683-BD36B1F1-E91A-4BAD-B72C-5B3D5AE65A3AQ24240095-83932F61-70DB-443C-92AF-D33344E9367FQ24241041-75DF1973-9763-49DB-BE1C-E5C292FB2876Q24243152-CFBADAF1-262B-4275-AD25-8CFF56F211B9Q24243823-0508E058-BD01-45AE-A8D9-4355A11C4076Q24244072-0C6EAAF8-29FC-491D-A483-62788FEB5C1EQ24247787-FB14DD06-3F58-4729-AB3E-A68D93656E79Q24248755-3510945A-5109-4333-9CB5-D970A42166D1Q24803302-E3E1A4F5-34FC-4A24-8661-67AACAE0CA31Q28372699-246B41CE-F24B-4D5F-8F40-36CF23A218A0Q28481584-EC5E7EC8-2D08-402C-9A39-C11415820A00Q30375083-31168F60-265A-4359-A9C2-9B2AF09336FEQ30492645-C2966AC9-671C-42B5-BFEC-DB0D5A800970Q30501297-75CE7FC4-64DF-42D9-B12F-BF24D9419072Q30862474-2F46EC9F-3EE9-4686-9E71-5C011263D963Q30867916-BB805657-4949-42FF-9178-01D9E28F01FAQ30952576-8D86C4EB-77CF-4FDA-8E59-0289F3549625Q30983779-EDED28D2-1CD8-484A-825B-1B141103B803Q30992683-9D61B3E1-551D-4CAC-AD38-B8950004F4B6Q30998569-5D19B901-A654-4D0F-9C32-75D583B96962Q31117818-5D76FE71-4A2A-4D7A-A0EE-E9AD9DBC70DFQ31143463-1E0755E8-DC71-421B-8039-5A916124FF49Q31147797-8E449085-5539-4DCA-A094-610846264C12Q31154155-B6F38882-9E8C-4740-9875-5E60704A0AD8Q31159481-7A6E79E2-3C33-42D8-ADD3-9614A2954CF7Q31161878-43DC57F1-56DE-4843-9E95-B331C73C4B41Q33223628-425391C5-0FFD-47FD-8BFD-840DBB41A071Q33235110-984F2B7D-8E37-4484-8160-3B0873DBEE08Q33366010-E5CEE382-59EF-486D-9B02-CD290D9D747BQ33538059-C601C771-2F3E-4939-A8F0-0E64EE6BCEC5Q33585800-7CB255D0-202D-491A-99A1-6F146251E845Q33606079-8ECB4A0D-318C-4E8C-98E1-718DE6911D42Q33662909-EB6E0C94-D3F6-4449-B893-E62888AD22D0Q33692289-3F09B648-2884-430E-BC9A-0D02B637D86DQ33693812-3572BD0C-CF94-4B67-9822-DBF0B1C5A21DQ33695777-251776FD-5240-40F0-947F-B3A82B038AD1
P2860
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Risperidone in the treatment of schizophrenia.
@ast
Risperidone in the treatment of schizophrenia.
@en
Risperidone in the treatment of schizophrenia.
@nl
type
label
Risperidone in the treatment of schizophrenia.
@ast
Risperidone in the treatment of schizophrenia.
@en
Risperidone in the treatment of schizophrenia.
@nl
prefLabel
Risperidone in the treatment of schizophrenia.
@ast
Risperidone in the treatment of schizophrenia.
@en
Risperidone in the treatment of schizophrenia.
@nl
P356
P1476
Risperidone in the treatment of schizophrenia.
@en
P2093
P304
P356
10.1176/AJP.151.6.825
P407
P577
1994-06-01T00:00:00Z